From guidance to action: preventing HIV and viral hepatitis among people who inject drugs in the Eastern European region
The objectives of the webinar are to:
Website
L'Agence européenne des drogues (EUDA) est l'autorité principale en matière de drogues illicites en Europe. Basée à Lisbonne, au Portugal, l'EUDA fournit des preuves et analyses scientifiques indépendantes sur tous les aspects de cette menace en constante évolution, tant pour les individus que pour la société dans son ensemble. L'EUDA contribue aux politiques de l'UE et des États membres afin de protéger les citoyens européens des dangers liés aux drogues. Elle est une agence de l'Union européenne.
Mission
Notre nouvelle mission se concentre sur la contribution à la préparation de l'Union européenne (UE) en matière de drogues par le biais de quatre actions principales : anticiper, alerter, répondre et apprendre.
Related Knowledge Share items
What Europeans think about drugs and drug policy: results from the first EUDA Drug Survey
Join us on 12 November as we present the results of the first EUDA Drug Survey, exploring public attitudes towards drugs and drug policy across Europe. Using the European Commission's Flash Eurobarometer methodology, the survey captures the views of the general population on drug-related problems and risks, drug availability and how society should respond.
Mental health and drug use in prison: understanding and responding to dual disorders
Date: 15 December 2026, 12:00–13:30 Lisbon time (WET) — 13:00–14:30 (CET).
This webinar will focus on the co-occurrence of mental health and substance use disorders among people in prison. It will also cover the broader mental health and well-being needs of people in prison, including those that may not be captured by a formal diagnosis.
Trauma-informed care — Building safer, more inclusive services through understanding, dialogue and practice
Date: 04 November 2026, 12:00–13:30 Lisbon time (WET) — 13:00–14:30 (CET).
Objectives
The webinar aims to:
Protecting young people from recruitment into criminal drug networks: Research gaps and priorities for stronger prevention and intervention in the European Union
Safe futures is an initiative supported by the European Union Drugs Agency to strengthen shared understanding of, and responses to, the recruitment and exploitation of young people into criminal drugs networks across Europe. The initiative...
Cannabis and mental health
Objective: This webinar will provide an overview of mental health risks associated with cannabis use. Participants will hear about the findings on how cannabis use is linked to anxiety, depression, psychotic symptoms and cannabis use disorder, and how cannabis type, potency, and use patterns might increase the risks.
European drug situation through institutional and civil society perspectives
Objective: To create an opportunity for civil society organisations (CSOs) and EUDA to exchange views on the current European drug situation and reflect on its implications from institutional, community and civil society perspectives.
Assessment of the threat posed by highly potent synthetic opioids in Europe
This threat assessment examines the potential risks posed by highly potent synthetic opioids (HPSOs) in Europe over the next two years. Drawing on early warning data, forensic and clinical evidence, and expert input, the report explores how...
Preventing opioid-related deaths in Europe — continuity of care, peer naloxone and rapid overdose alerts
Objective: To mark International Overdose Awareness Day on 31 August, this webinar convenes policy, practice, research and community voices to discuss compassionate, evidence-informed and practical actions that can prevent opioid-related deaths across Europe.
Understanding dual disorders
Objective: This webinar will provide an overview of dual disorders (DD), introduce the recently launched EUDA health and social responses miniguide, and offer practical insights from EU-based initiatives. Participants will gain a clearer understanding of the challenges associated with co-occurring mental health and substance use disorders, as well as examples of how these are being addressed in different contexts.